Companion Diagnostics Market

Report Code MD 5463
Published in Apr, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Global Forecast to 2029

Overview

The global size of companion diagnostics market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. In recent years, there has been a rapid advancement in medical technology, leading to significant changes in therapies and medicine. This progress has contributed to the substantial growth of the companion diagnostics market. Factors such as the increasing importance of companion diagnostics in drug development, the rising prevalence of cancer, and the growing adoption of targeted therapies are driving the growth of the market.

Attractive Opportunities in the Companion Diagnostics Market

Asia Pacific

The Asia Pacific market is expected to witness high growth during the forecast period owing to substantial population base, increasing awareness about companion diagnostics, and investments in healthcare infrastructure are contributing factors.

The increasing global incidence of cancer is driving the growth of the companion diagnostics market.

Product launches and partnerships were the most widely adopted growth strategies by market players.

The North American market is projected to hold the largest market share during the review period.

Emerging markets are expected to offer lucrative growth opportunities for players in the companion diagnostics market.

Global Companion Diagnostics Market Dynamics

Driver: Increasing significance of personalized medicine

Growing awareness of the advantages of personalized medicine is a key factor driving the increasing utilization of companion diagnostics and genomics & proteomics technologies. Companion diagnostic tests, which involve analyzing specific indications for particular drugs in individual patients, are integral to tailored treatment plans for numerous chronic diseases and conditions. These tests empower healthcare providers to make informed clinical decisions and lower the risk of unnecessary adverse events. The shift towards personalized medicine is reshaping healthcare practices, with a focus on delivering more precise and effective treatments. This shift further fuels the demand for companion diagnostics products as they enable healthcare providers to make informed and targeted treatment choices, ultimately improving patient outcomes.

Restraint: High capital investment and low cost-benefit ratio

Substantial capital investments are necessary for the discovery, development, and validation of biomarkers. The significant challenge arises from the high drug attrition rate during clinical trials, where nearly 30% of drugs fail in phase III. This poses substantial financial hurdles for diagnostic manufacturers. Manufacturers must achieve successful phase III clinical trials to obtain approval for in vitro diagnostics (IVD) from regulators, which relies on well-validated biomarker tests. Running clinical trials and meeting rigorous regulatory requirements demand considerable investments, impacting the ability of small companies to develop biomarkers and affecting innovation. Consequently, the companion diagnostics market for biomarker detection is hindered not only by the substantial capital required but also by the low cost-benefit ratio.

 

Opportunity: Increasing importance of companion diagnostics in drug development

The importance of companion diagnostics in aiding healthcare providers with treatment decisions for patients is steadily growing. The co-development of companion diagnostics alongside therapeutic products has the potential to significantly transform the drug development process and streamline the commercialization of drug candidates. This co-development can lead to the creation of safer drugs with enhanced therapeutic efficacy in a quicker and more cost-effective manner. As the demand rises for high-priced specialist therapies and safer medications, the market for companion diagnostics is poised for substantial growth.

Challenge: The shortage of adequately trained professionals

Companion diagnostic testing is a complex and technical process that requires trained professionals. Proficiency in companion diagnostic technologies is essential for conducting tests accurately. There is a lack of awareness among clinicians about the latest advancements in companion diagnostic tests, creating a gap in operational knowledge for clinical laboratories. Additionally, the reluctance to transition from manual operations to automation poses a challenge for market growth. Many providers struggle to switch from manual or traditional methods to IT-based approaches or may resist the change altogether. Hence, the scarcity of skilled, well-trained, and technically knowledgeable laboratory technicians to operate advanced companion diagnostic products is limiting their widespread adoption, particularly in emerging markets.

Global Companion Diagnostics Market Ecosystem Analysis

 

 

In 2023, the assays, kits & reagents segment held the largest portion of the companion diagnostics industry, by product & service

Based on product & service, the companion diagnostics market is divided into assays, kits & reagents, instruments/systems and software & services. In 2023, the assays, kits & reagents segment dominated the companion diagnostics market, primarily attributed to the wide variety of available products and the growing utilization of assays and kits across various therapeutic areas.

In 2023, the PCR segment held the companion diagnostics industry largest market share, by technology

The companion diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies, based on technology. In 2023, the PCR segment captured the highest market share, primarily due to its ease of use and extensive availability of PCR kits & reagents for companion diagnostic testing. Additionally, PCR's growing applications in detecting gene mutants with limited or low allele frequencies further contributed to its dominance in the market.

North America region holds the largest share of the Companion Diagnostics Market.

The global companion diagnostics market is segmented into six major regions—North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC countries. In 2023, North America, particularly the U.S. and Canada, leads the global companion diagnostics market. The region's technological advancement and a high number of product approvals by regulatory authorities, such as the FDA, are driving market growth. For example, in October 2022, F. Hoffmann-La Roche Ltd. received FDA approval for the first companion diagnostic to identify patients with HER2 low metastatic breast cancer.

 
 

Recent Developments of Companion Diagnostics Market industry

  • In August 2023, Agilent Technologies, Inc. (US) received European IVDR Certification for Companion Diagnostic Assay.
  • In August 2023, QIAGEN (Netherlands). received FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT (avapritinib) in gastrointestinal stromal tumors.

Key Market Players

Want to explore hidden markets that can drive new revenue in Companion Diagnostics Market?

Scope of the Report

Report Attribute Details
Market Revenue in 2024 $7.5 billion
Projected Revenue by 2029 $13.6 billion
Revenue Rate Poised to grow at a CAGR of 12.6%
Market Driver Increasing significance of personalized medicine
Market Opportunity Increasing importance of companion diagnostics in drug development

Key Questions Addressed by the Report

What is the projected market revenue value of the global companion diagnostics market?
The global companion diagnostics market is expected to reach a total revenue value of $13.6 billion by 2029.
What is the estimated growth rate (CAGR) of the global companion diagnostics market?
The market is projected to grow at a compound annual growth rate (CAGR) of 12.6%, with an estimated revenue size of $7.5 billion by 2024.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
30
RESEARCH METHODOLOGY
36
EXECUTIVE SUMMARY
50
PREMIUM INSIGHTS
55
MARKET OVERVIEW
59
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Ability of CDx tests to reduce healthcare costs and increase efficiency
    - Growing focus on targeted therapy
    - Rising demand for personalized medicine
    - Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine
    - Growing application areas for companion diagnostics
    RESTRAINTS
    - Significant capital investment and low cost-benefit ratio
    - High cost of companion diagnostic tests
    - Unfavorable reimbursements
    - High cost of immunotherapy treatment
    OPPORTUNITIES
    - Increasing demand for next-generation sequencing
    - Growing significance of companion diagnostics in drug development
    - Advancements in genomics research and rising clinical trials
    CHALLENGES
    - Shortage of healthcare professionals
    - Limited awareness in emerging markets
  • 5.3 PRICING ANALYSIS
  • 5.4 PATENT ANALYSIS
  • 5.5 TRADE ANALYSIS
    TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    ASIA PACIFIC
    - China
    - Japan
    - India
    LATIN AMERICA
    - Brazil
    - Mexico
    MIDDLE EAST
    AFRICA
  • 5.11 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Polymerase chain reaction (PCR)
    - Next-generation sequencing (NGS)
    COMPLIMENTARY TECHNOLOGIES
    - In situ hybridization (ISH)
    ADJACENT TECHNOLOGIES
    - Immunohistochemistry (IHC)
  • 5.12 KEY CONFERENCES & EVENTS IN 2024–2025
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.15 INVESTMENT AND FUNDING SCENARIO
COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
88
  • 6.1 INTRODUCTION
  • 6.2 ASSAYS, KITS, AND REAGENTS
    INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
  • 6.3 INSTRUMENTS & SYSTEMS
    LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH
  • 6.4 SOFTWARE & SERVICES
    NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
100
  • 7.1 INTRODUCTION
  • 7.2 POLYMERASE CHAIN REACTION
    GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
  • 7.3 IN SITU HYBRIDIZATION
    INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH
  • 7.4 NEXT-GENERATION SEQUENCING
    ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH
  • 7.5 IMMUNOHISTOCHEMISTRY
    INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
  • 7.6 OTHER TECHNOLOGIES
COMPANION DIAGNOSTICS MARKET, BY INDICATION
119
  • 8.1 INTRODUCTION
  • 8.2 CANCER
    LUNG CANCER
    - Growing demand for effective therapeutic drugs to increase CDx adoption
    BREAST CANCER
    - Wide prevalence of breast cancer to boost market growth
    BLOOD CANCER
    - Growing incidence of blood cancer to drive market
    COLORECTAL CANCER
    - Rising need for molecular profiling of primary tumors to drive segment growth
    OTHER CANCERS
  • 8.3 NEUROLOGICAL DISEASES
    GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
  • 8.4 CARDIOVASCULAR DISEASES
    INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
  • 8.5 INFECTIOUS DISEASES
    INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH
  • 8.6 OTHER INDICATIONS
COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE
150
  • 9.1 INTRODUCTION
  • 9.2 TISSUE SAMPLES
    COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET
  • 9.3 BLOOD SAMPLES
    LESS INVASIVE METHOD—KEY FACTOR DRIVING ADOPTION
  • 9.4 OTHER SAMPLE TYPES
COMPANION DIAGNOSTICS MARKET, BY END USER
161
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET
  • 10.3 REFERENCE LABORATORIES
    RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
  • 10.4 CONTRACT RESEARCH ORGANIZATIONS
    RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH
  • 10.5 OTHER END USERS
COMPANION DIAGNOSTICS MARKET, BY REGION
175
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Increasing use of companion diagnostics for cancer treatment to boost market growth
    CANADA
    - Increasing government initiatives to drive market
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Increasing healthcare expenditure to drive market
    UK
    - Growing life science industry and increasing focus on research to propel market
    SWITZERLAND
    - Strong research-oriented pharma industry to support market growth
    FRANCE
    - Increasing government funding for research to support market growth
    ITALY
    - Growing geriatric population in region to drive market
    SPAIN
    - Increasing focus on advancement of personalized medicine to drive market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Advancements in healthcare facilities to drive market
    JAPAN
    - Increasing research initiatives to support market growth
    INDIA
    - Increased demand for early cancer diagnosis to fuel market growth
    AUSTRALIA
    - Initiatives to enhance healthcare access and infrastructure for aging population to drive market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Increasing incidence of lifestyle diseases to favor market growth
    MEXICO
    - Growing medical tourism to fuel demand for companion diagnostics
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
    MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 11.7 GCC COUNTRIES
    GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
    GCC COUNTRIES: RECESSION IMPACT
COMPETITIVE LANDSCAPE
264
  • 12.1 INTRODUCTION
  • 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
    - Overall footprint
    - Product footprint
    - Technology footprint
    - Indication footprint
    - Regional footprint
  • 12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
    F. HOFFMANN-LA ROCHE LTD.
    AGILENT TECHNOLOGIES, INC.
    QIAGEN
    THERMO FISHER SCIENTIFIC INC.
    ABBOTT
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
COMPANY PROFILES
279
  • 13.1 KEY PLAYERS
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    QIAGEN
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    ABBOTT
    - Business overview
    - Products/Services/Solutions offered
    - MnM view
    DANAHER
    - Business overview
    - Products/Services/Solutions offered
    GUARDANT HEALTH
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ILLUMINA, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products/Services/Solutions offered
    ICON PLC
    - Business overview
    - Products/Services/Solutions offered
    MYRIAD GENETICS, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    SYSMEX CORPORATION
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    ALMAC GROUP
    ARUP LABORATORIES
    ABNOVA CORPORATION
    BIOGENEX
    INVIVOSCRIBE, INC.
    ARCHERDX, INC.
    Q² SOLUTIONS
    AMOY DIAGNOSTICS CO., LTD.
    UNIOGEN
    ASURAGEN, INC.
    MESO SCALE DIAGNOSTICS, LLC
    CREATIVE BIOLABS
    NG BIOTECH
APPENDIX
340
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0–85+), 2022 VS. 2045
  • TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS
  • TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS
  • TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
  • TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS
  • TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION
  • TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION)
  • TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION)
  • TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: CLASSIFICATION OF DEVICES
  • TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%)
  • TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
  • TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY
  • TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY
  • TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY
  • TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION
  • TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
  • TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE
  • TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE
  • TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE
  • TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE
  • TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040
  • TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS
  • TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS
  • TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS
  • TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045
  • TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 221 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 222 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 223 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 224 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 226 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 227 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 228 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 229 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 230 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 233 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 234 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 235 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 236 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 237 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 242 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 243 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 245 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 246 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 247 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 248 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 249 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 250 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 251 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 253 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 254 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 255 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 256 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 257 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 259 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 260 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 261 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 262 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 263 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 264 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 265 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 267 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 268 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 269 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 270 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 271 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 272 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 279 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 280 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 281 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 282 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 283 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 285 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 286 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 287 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 288 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 289 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 290 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 291 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 292 MEXICO: NEW CANCER CASES, 2022
  • TABLE 293 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 294 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 295 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 296 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 298 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 299 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 300 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 301 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 302 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 306 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 307 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 309 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 310 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 311 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 312 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 314 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 317 COMPANION DIAGNOSTICS MARKET: STRATEGIES ADOPTED
  • TABLE 318 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 319 COMPANION DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 320 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 321 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
  • TABLE 322 COMPANION DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
  • TABLE 323 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 324 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • TABLE 325 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
  • TABLE 326 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2024
  • TABLE 327 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 328 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 329 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 330 F. HOFFMANN-LA ROCHE LTD.: DEALS
  • TABLE 331 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 332 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 333 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS
  • TABLE 334 AGILENT TECHNOLOGIES, INC.: DEALS
  • TABLE 335 QIAGEN: COMPANY OVERVIEW
  • TABLE 336 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 337 QIAGEN: PRODUCT LAUNCHES & APPROVALS
  • TABLE 338 QIAGEN: DEALS
  • TABLE 339 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 340 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 341 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS
  • TABLE 342 THERMO FISHER SCIENTIFIC INC.: DEALS
  • TABLE 343 ABBOTT: COMPANY OVERVIEW
  • TABLE 344 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 345 DANAHER: COMPANY OVERVIEW
  • TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 347 GUARDANT HEALTH: COMPANY OVERVIEW
  • TABLE 348 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 349 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS
  • TABLE 350 GUARDANT HEALTH: DEALS
  • TABLE 351 GUARDANT HEALTH: OTHER DEVELOPMENTS
  • TABLE 352 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 353 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 354 ILLUMINA, INC.: PRODUCT LAUNCHES
  • TABLE 355 ILLUMINA, INC.: DEALS
  • TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 357 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 358 ICON PLC: COMPANY OVERVIEW
  • TABLE 359 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 360 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 361 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 362 MYRIAD GENETICS, INC.: PRODUCT APPROVALS
  • TABLE 363 MYRIAD GENETICS, INC.: DEALS
  • TABLE 364 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 365 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 366 SYSMEX CORPORATION: DEALS
  • TABLE 367 SYSMEX CORPORATION: OTHER DEVELOPMENTS
  • TABLE 368 ALMAC GROUP: COMPANY OVERVIEW
  • TABLE 369 ARUP LABORATORIES: COMPANY OVERVIEW
  • TABLE 370 ABNOVA CORPORATION: COMPANY OVERVIEW
  • TABLE 371 BIOGENEX: COMPANY OVERVIEW
  • TABLE 372 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
  • TABLE 373 ARCHERDX, INC.: COMPANY OVERVIEW
  • TABLE 374 Q² SOLUTIONS: COMPANY OVERVIEW
  • TABLE 375 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 376 UNIOGEN: COMPANY OVERVIEW
  • TABLE 377 ASURAGEN, INC.: COMPANY OVERVIEW
  • TABLE 378 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW
  • TABLE 379 CREATIVE BIOLABS: COMPANY OVERVIEW
  • TABLE 380 NG BIOTECH: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN METHODOLOGY
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
  • FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029
  • FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029
  • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD
  • FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015−2022)
  • FIGURE 23 GLOBAL CANCER INCIDENCE (2008−2030)
  • FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014–DECEMBER 2023)
  • FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES
  • FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 ECOSYSTEM MAP
  • FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS
  • FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
  • FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS (2019–2023)
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • FIGURE 36 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 COMPANION DIAGNOSTICS MARKET: OVERALL FOOTPRINT
  • FIGURE 38 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 41 PRODUCT/BRAND COMPARATIVE ANALYSIS, BY PARAMETER
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
  • FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 51 ICON PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 52 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)

This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the companion diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.

The four steps involved in estimating the market size are:

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the companion diagnostics market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the companion diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals, clinics and ambulatory surgery centers (ASCs)) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, Latin America and the GCC Countries. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

The following is a breakdown of the primary respondents:

Companion Diagnostics Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

All major product manufacturers offering various companion diagnostics products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value companion diagnostics market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of companion diagnostics market at the regional and country-level.
  • Relative adoption pattern of each companion diagnostics market among key application segments at the regional and/or country-level.
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Global Companion Diagnostics Market Size: Top-Down Approach

Companion Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the companion diagnostics device industry.

Market Definition

A companion diagnostic (CDx) assay is an in vitro diagnostic device (IVD) that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug. CDx uses technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization. The biomarker assessment enable physicians to identify a specific biomarker that could indicate the patients’ most likely outcome-based combination of therapies or even a specific treatment regimen.

Key Stakeholders

  • Manufacturing Companies of Companion diagnostics and Related Devices
  • Original Equipment Manufacturers
  • Suppliers and Distributors of Electroceutical Devices
  • Healthcare Service Providers
  • Teaching Hospitals and Academic Medical Centers (AMCs)
  • Health Insurance Payers
  • Research and Consulting Firms
  • Medical Research Institutes
  • Healthcare Institutes/Providers (Hospitals, Medical Groups, Physicians’ Practices, Diagnostic Centers, and Outpatient Clinics)
  • Venture Capitalists
  • Community Centers

Report Objectives

  • To define, describe, segment, and forecast the companion diagnostics market by product & service, technology, indication, sample type, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges).
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and GCC countries.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze company developments such as acquisitions, collaborations, partnerships, agreements, and product launches & approvals in the companion diagnostics market
  • To benchmark players within the companion diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Companion diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, the Rest of Latin America, and Middle East & Africa.

Company Profiles

  • Product portfolio matrix for leading market players.

Previous Versions of this Report

Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026

Report Code MD 5463
Published in Feb, 2022, By MarketsandMarkets™

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025

Report Code MD 5463
Published in Jun, 2020, By MarketsandMarkets™

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024

Report Code MD 5463
Published in Sep, 2019, By MarketsandMarkets™

Companion Diagnostics Market Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022

Report Code MD 5463
Published in Aug, 2017, By MarketsandMarkets™

Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019

Report Code BT 2698
Published in Sep, 2014, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Companion Diagnostics Market

Alisa

Jul, 2022

What is the Companion Diagnostics Market trend by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Regional Analysis - Global Forecast to 2031.

Alan

Dec, 2022

Companion Diagnostics Market Report provides the global forecasts for the next five years. Companies like ResearchDx is profiled as one of the key players in this report. Included the comprehensive 360 degree competitive mapping by profiling major players of Companion Diagnostics Market. Key Questions Addressed in the Report: • Where will all these products & services take the industry in the mid to long term? • What are the growth opportunities in the Companion Diagnostics Market across major regions in the future? • Which are the key players in the market and how intense is the competition? • What are the current industry developments for companion diagnostics? We have given a comprehensive 360 degree competitive mapping by profiling major players of Companion Diagnostics Market..

DMCA.com Protection Status